Evommune to present Phase 2a EVO301 atopic dermatitis data at EADV 2026 late-breaker session

Phase 2b dose-ranging study is expected to start in mid-2027, setting up the next development step for EVO301.

Readout supports IL-18 inhibition as a potential new approach in atopic dermatitis, targeting broader inflammatory pathways than Th2-focused therapies.

Evommune set a late-breaking oral presentation of Phase 2a EVO301 data in moderate-to-severe atopic dermatitis at EADV 2026.

Results were already disclosed as positive top-line findings earlier in 2026; full data will be presented on Oct. 1 in Vienna.